Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.

Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles 

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London